Skip to main content
Withus Pharmaceutical. Co., LTD logo

Withus Pharmaceutical. Co., LTD — Investor Relations & Filings

Ticker · 330350 ISIN · KR7330350000 KO Manufacturing
Open in API
Filings indexed 119 across all filing types
Latest filing 2025-03-13 Proxy Solicitation & In…
Country KR South Korea
Listing KO 330350

About Withus Pharmaceutical. Co., LTD

https://withuspharm.com/

Withus Pharmaceutical. Co., LTD. is a pharmaceutical company engaged in the manufacturing and sale of prescription drugs. The company's product portfolio addresses a range of therapeutic areas, with a focus on circulatory agents, endocrine system treatments, and musculoskeletal drugs. Additionally, its offerings include antibiotics and medications for allergies.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Withus Pharmaceutical Co., Ltd. It contains the agenda for the 21st Annual General Meeting, including the approval of financial statements, election of directors, and remuneration limits. It also includes detailed financial statements (balance sheet, income statement, etc.) as part of the 'Management Reference Materials' (경영참고사항) required for shareholders to review before the meeting. This is a standard proxy solicitation document sent to shareholders to inform them of the meeting and request their votes.
2025-03-13 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Withus Pharmaceutical. It outlines the date, location, and agenda items (financial statement approval, director appointments, and compensation limits). This type of document is sent to shareholders to provide information and request votes for an upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2025-03-10 Korean
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal notification filed by Withers Pharmaceutical regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date where many companies hold their AGMs). It explains the reasoning for this scheduling and provides the meeting date. Since it is a regulatory announcement regarding the logistics of a shareholder meeting rather than the meeting materials themselves or the voting results, it falls under the general regulatory filing category.
2025-03-10 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Withus Pharmaceutical) regarding a significant change in revenue or profit/loss structure (30% or more). This is a standard disclosure requirement in the Korean stock market (KRX) for material financial changes. Since it provides key financial highlights and reasons for the change rather than a full annual report or a simple announcement of a report's availability, it falls under the 'Earnings Release' category as it serves as the initial announcement of financial performance metrics. FY 2024
2025-02-12 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for the purpose of holding an upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or proxy statements, but rather serves as a formal regulatory notice of the procedural steps for the meeting. Given it is a standard regulatory disclosure regarding corporate governance and meeting preparation, it fits best under the RNS category.
2024-12-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed in South Korea. This type of filing is a mandatory disclosure by company insiders (directors/executives) regarding their personal share transactions (insider trading). According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2024-11-20 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.